Market Overview

UPDATE: Aegis Capital Initiates Amarin Corporation with Buy, $25 PT; Risk-Mitigated Opportunity

Related AMRN
Amarin Moves Higher On Speculation Of Special Protocol Assessment
Stocks To Watch For June 26, 2014
Related AMRN
Top Performing Industries For June 12, 2014
Ligand-AstraZeneca Collaborate - Analyst Blog

Aegis Capital said on Monday that it initiated coverage on Amarin Corporation (NASDAQ: AMRN) with a Buy rating and a price target of $25.

Aegis Capital said, "In our view, Amarin constitutes one of the most risk-mitigated opportunities in the biotechnology sector, as the firm's lead product candidate has already successfully demonstrated safety and efficacy in two randomized, placebo-controlled Phase 3 clinical trials. These studies were conducted under Special Protocol Assessments (SPAs) from the U.S. FDA."

Amarin Corporation closed at $15.12 on Friday.

Posted-In: Aegis CapitalAnalyst Color Price Target Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (AMRN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters